Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study

Pas encore traduit Pas encore traduit
Auteurs
Catégorie Primary study
Registry of Trialsclinicaltrials.gov
Year 2007

Cet article est inclus dans 3 Systematic reviews Systematic reviews (3 references)

This article is part of the following publication threads:
  • EINSTEIN PE [Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism] (12 documents)
This article is part of the following matrixes of evidence:
Loading references information
This is a multicenter, randomized, open-label, assessor-blind, event-driven, non-inferiority program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with confirmed acute symptomatic pulmonary embolism (PE) with or without symptomatic Deep-Vein Thrombosis (DVT) (Einstein-PE).
Epistemonikos ID: 2a9c84a30d8d7948b1f1d841c9e0fc412bb7830f
First added on: May 17, 2016